Teva Pharmaceuticals Industries Inc. won final regulatory clearance to market its generic version of cholesterol medication Zocor after a federal judge threw out a motion from a rival company to block the approval.
Judge Royce C. Lamberth of the U.S. District Court for the District of Columbia denied a motion for a temporary restraining order filed by another generic manufacturer, Sandoz Inc. to block the FDA from approving Teva’s generic form of Zocor. The denial of the motion cannot be appealed. Merck & Co.’s Zocor lost patent protection on Friday. It generated $4.4 billion last year.
